Literature DB >> 16973966

NPC1L1: evolution from pharmacological target to physiological sterol transporter.

Murray W Huff1, Rebecca L Pollex, Robert A Hegele.   

Abstract

Niemann-Pick C1-like 1 protein (NPC1L1) was recently shown to be the molecular target of the cholesterol absorption inhibitor class of drugs, of which ezetimibe is the first widely used member. Since its discovery, NPC1L1 has also been shown to play a focal physiological role in intestinal absorption of sterols, including plant sterols and cholesterol. Evidence in support of this new metabolic pathway has been garnered not only through human, animal, and cell studies of function but also through the use of human genetics as an approach to study the association of NPC1L1 sequence variation with metabolic and drug-response phenotypes. The example of NPC1L1 shows how the elucidation of a pharmacological target can serve as a means to gain understanding of a key physiological pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16973966     DOI: 10.1161/01.ATV.0000245791.53245.ee

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  11 in total

Review 1.  Dyslipidaemia of diabetes and the intestine.

Authors:  Gerald H Tomkin; Daphne Owens
Journal:  World J Diabetes       Date:  2015-07-10

2.  Efficacy of ezetimibe is not related to NPC1L1 gene polymorphisms in a pilot study of Chilean hypercholesterolemic subjects.

Authors:  Tomás Zambrano; Nicolás Saavedra; Fernando Lanas; José Caamaño; Luis A Salazar
Journal:  Mol Diagn Ther       Date:  2015-02       Impact factor: 4.074

3.  Molecular cloning and characterization of NPC1L1 in the Chinese tree shrew (Tupaia belangeri chinensis).

Authors:  Xiuying Kui; Dandan Qiu; Wenguang Wang; Na Li; Pinfen Tong; Xiaomei Sun; Liangzi Jin; Wei Deng; Jiejie Dai; Caixia Lu
Journal:  Mol Biol Rep       Date:  2021-10-30       Impact factor: 2.316

Review 4.  Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics.

Authors:  Yajun Duan; Ke Gong; Suowen Xu; Feng Zhang; Xianshe Meng; Jihong Han
Journal:  Signal Transduct Target Ther       Date:  2022-08-02

Review 5.  Non-vesicular sterol transport in cells.

Authors:  William A Prinz
Journal:  Prog Lipid Res       Date:  2007-07-18       Impact factor: 16.195

Review 6.  Molecular processes that handle -- and mishandle -- dietary lipids.

Authors:  Kevin Jon Williams
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

Review 7.  Intestinal lipid absorption.

Authors:  Jahangir Iqbal; M Mahmood Hussain
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-01-21       Impact factor: 4.310

8.  The chylomicron: relationship to atherosclerosis.

Authors:  Gerald H Tomkin; Daphne Owens
Journal:  Int J Vasc Med       Date:  2011-10-05

9.  A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population.

Authors:  F Raal; C Schamroth; J Patel; P Becker
Journal:  Cardiovasc J Afr       Date:  2007 Sep-Oct       Impact factor: 1.167

10.  Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe).

Authors:  Kyung-Jin Kim; Sang-Hyun Kim; Young Won Yoon; Seung-Woon Rha; Soon-Jun Hong; Choong-Hwan Kwak; Weon Kim; Chang-Wook Nam; Moo-Yong Rhee; Tae-Ho Park; Taek-Jong Hong; Sungha Park; Youngkeun Ahn; Namho Lee; Hui-Kyung Jeon; Dong-Woon Jeon; Kyoo-Rok Han; Keon-Woong Moon; In-Ho Chae; Hyo-Soo Kim
Journal:  Cardiovasc Ther       Date:  2016-10       Impact factor: 3.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.